GW Pharmaceuticals
Prescription cannabinoid medicines for various neurological conditions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 Valuation: €0.0 9.6x EV/EBITDA | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
$7.2b Valuation: $7.2b 10.1x EV/Revenue 83.7x EV/EBITDA | Acquisition | ||
| Total Funding | 000k | ||
| USD | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 88 % | 1973 % | 69 % | 2 % | 32 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (1988 %) | (1960 %) | (35 %) | (7 %) | 12 % | 21 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (2125 %) | (2033 %) | (3 %) | (11 %) | 3 % | 17 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 1302 % | 744 % | 34 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
GW Pharmaceuticals is a British biopharmaceutical company founded in 1998 by doctors Geoffrey Guy and Brian Whittle. In May 2021, Jazz Pharmaceuticals acquired the company for $7.2 billion. GW is a world leader in developing and commercializing therapeutics derived from its proprietary cannabinoid product platform.
The company received a license from the UK Home Office in 1998, permitting it to cultivate, possess, and supply cannabis for medical research. Its first major product, Sativex (nabiximols), became the first natural cannabis plant derivative to gain market approval in any country. Sativex is an oral spray approved in multiple countries for treating spasticity associated with multiple sclerosis. In June 2018, the company made history again when its product Epidiolex became the first cannabis-derived drug approved for sale by the U.S. Food and Drug Administration (FDA). Epidiolex is an oral solution of cannabidiol (CBD) used to treat seizures associated with rare and severe forms of childhood-onset epilepsy, such as Dravet syndrome and Lennox-Gastaut syndrome.
GW Pharmaceuticals' business model centers on the discovery, development, and commercialization of plant-derived cannabinoid medicines. Revenue is generated through the sale of its approved products, which are distributed via strategic collaborations with other pharmaceutical companies like Bayer and Jazz Pharmaceuticals. The company focuses its research and development on addressing significant unmet medical needs in a range of disease areas, primarily within neuroscience. The company's strategy includes expanding the use of its existing drugs to new indications and advancing a pipeline of other cannabinoid candidates for conditions like glioblastoma and schizophrenia.
Keywords: cannabinoid medicine, biopharmaceutical, epilepsy treatment, multiple sclerosis, Sativex, Epidiolex, Dravet syndrome, Lennox-Gastaut syndrome, nabiximols, cannabidiol, pharmaceutical research, neuroscience, plant-derived therapeutics, Jazz Pharmaceuticals, Geoffrey Guy, Brian Whittle, clinical trials, spasticity, seizure disorders, orphan drugs